Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.
Desai
Apurva A
AA
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA. adesai@medicine.bsd.uchicago.edu
Stadler
Walter M
WM
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D004791:Enzyme Inhibitors; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D066246:ErbB Receptors; D000077210:Sunitinib
Nature. 1999 May 20;399(6733):271-5
10353251
Clin Cancer Res. 2004 Sep 15;10 (18 Pt 2):6290S-5S
15448019
J Clin Oncol. 2005 Sep 1;23(25):5892-9
16043829
J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16
10655437
Cancer Res. 2000 Dec 15;60(24):7075-83
11156414
Lancet. 1998 Nov 21;352(9141):1691-6
9853456
Ann Surg Oncol. 2004 Jan;11(1):71-7
14699037
J Urol. 2003 Oct;170(4 Pt 1):1141-5
14501711
Invest New Drugs. 2003 Aug;21(3):341-5
14578682
N Engl J Med. 2004 Jun 3;350(23 ):2335-42
15175435
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
14974761
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9
8855223
Am J Nephrol. 2004 Jan-Feb;24(1):1-13
14654728
J Clin Oncol. 2002 Nov 15;20(22):4478-84
12431972
Cancer Res. 1998 Feb 15;58(4):808-14
9485039
Cancer Res. 1997 Oct 15;57(20):4593-9
9377574
J Nucl Med. 2004 Jan;45(1):17-21
14734662
Nat Genet. 1994 May;7(1):85-90
7915601
Oncogene. 2003 Jul 31;22(31):4918-23
12894235
Science. 2004 Jun 4;304(5676):1497-500
15118125
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4
7937876
Biochim Biophys Acta. 1996 Mar 18;1242(3):201-10
8603073
Clin Cancer Res. 2004 Apr 15;10 (8):2584-6
15102658
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
J Clin Oncol. 2001 Feb 1;19(3):843-50
11157038
Invest New Drugs. 2003 Feb;21(1):99-101
12795534
Pharmacol Ther. 2004 Apr;102(1):37-46
15056497
Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):443-8
12522270
N Engl J Med. 2003 Jul 31;349(5):427-34
12890841
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
Cochrane Database Syst Rev. 2000;(3):CD001425
10908496
Oncologist. 2004;9(3):271-81
15169982
J Urol. 2000 Feb;163(2):408-17
10647643
Cancer Res. 2002 May 15;62(10 ):2957-61
12019178
J Clin Oncol. 1999 Sep;17(9):2639-48
10561337
Semin Oncol. 2000 Apr;27(2):124-37
10768592
J Clin Oncol. 2003 Nov 1;21(21):3955-64
14517187
Cancer. 1994 Apr 1;73(7):1913-8
8137218
Cancer. 2003 Oct 15;98(8):1611-9
14534876
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
7612182
Int J Clin Pharmacol Ther. 2002 Dec;40(12):580-1
12503822
Clin Cancer Res. 2003 Jan;9(1):327-37
12538485
Biochem Biophys Res Commun. 2004 Apr 30;317(2):358-62
15063765
J Clin Oncol. 2003 Aug 15;21(16):3127-32
12915604